Home › Funds › HSG Holding Ltd › AVBP
HSG Holding Ltd position in AVBP
ARRIVENT BIOPHARMA INC · Health Care
HSG Holding Ltd reported holding 663,308 shares of AVBP (ARRIVENT BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$20.1M, representing 1.59% of its reported portfolio and ranking #10 among its reported holdings. HSG Holding Ltd has disclosed AVBP holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How HSG Holding Ltd's AVBP position evolved
HSG Holding Ltd first disclosed a stake in AVBP in Q1 2024 at 663,308 shares (US$10.5M). The position peaked in Q2 2026 at 663,308 shares, worth US$23.0M. Across 11 filings, HSG Holding Ltd held the position steady without any share-count change. The most recent filing (Q3 2026) shows 663,308 shares valued at US$20.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 663.31K | $10.46M | New |
| Q2 2024 | 663.31K | $14.84M | Hold |
| Q3 2024 | 663.31K | $19.04M | Hold |
| Q4 2024 | 663.31K | $16.79M | Hold |
| Q1 2025 | 663.31K | $13.98M | Hold |
| Q2 2025 | 663.31K | $14.44M | Hold |
| Q3 2025 | 663.31K | $12.99M | Hold |
| Q4 2025 | 663.31K | $16.72M | Hold |
| Q1 2026 | 663.31K | $13.98M | Hold |
| Q2 2026 | 663.31K | $23.04M | Hold |
| Q3 2026 | 663.31K | $20.08M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVBP and 13F data
AVBP (ARRIVENT BIOPHARMA INC) is a Health Care company. 56 other funds we track also report a position in AVBP — the largest reported positions include MONTANOVA CAPITAL, LLC (US$156.9M), INFINITUM ASSET MANAGEMENT, LLC (US$154.2M), Hillhouse Capital (HHLR Advisors) (US$136.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVBP
- MONTANOVA CAPITAL, LLC 4.52M sh · $156.87M · Q2 2026
- INFINITUM ASSET MANAGEMENT, LLC 4.44M sh · $154.19M · Q2 2026
- Hillhouse Capital (HHLR Advisors) 3.93M sh · $136.50M · Q2 2026
- ORBIMED ADVISORS LLC 3.03M sh · $105.17M · Q2 2026
- Octagon Capital Advisors LP 1.97M sh · $68.47M · Q2 2026
- Sofinnova Investments, Inc. 1.70M sh · $58.95M · Q2 2026
- Vivo Capital, LLC 1.79M sh · $54.11M · Q3 2026
- Novo Holdings A/S 1.50M sh · $52.11M · Q2 2026
- General Catalyst Group Management, LLC 1.49M sh · $51.93M · Q2 2026
- Logos Global Management LP 1.00M sh · $34.74M · Q2 2026
- Foresite Capital Management VI LLC 301.34K sh · $10.47M · Q2 2026
- Seven Fleet Capital Management LP 246.61K sh · $8.57M · Q2 2026
More on HSG Holding Ltd
FAQ
How long has HSG Holding Ltd held AVBP?
HSG Holding Ltd has disclosed AVBP holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is HSG Holding Ltd's current position in AVBP?
As of Q3 2026, HSG Holding Ltd holds 663.31K shares of AVBP (ARRIVENT BIOPHARMA INC), valued at $20.08M, representing 1.59% of its reported portfolio and ranking #10.
Has HSG Holding Ltd been buying or selling AVBP?
In the latest 13F filing (Q3 2026), HSG Holding Ltd held unchanged its position in AVBP. The position peaked in Q2 2026 at 663.31K shares.
Which other funds hold AVBP?
Other major institutional holders of AVBP include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, Hillhouse Capital (HHLR Advisors), among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.